[go: up one dir, main page]

WO2007093020A1 - Système de conditionnement, trousse de médicaments ou présentation d'administration médicamenteuse appropriée pour le traitement de l'hypertension et de maladies cardiovasculaires et la réduction de l'agrégation plaquettaire - Google Patents

Système de conditionnement, trousse de médicaments ou présentation d'administration médicamenteuse appropriée pour le traitement de l'hypertension et de maladies cardiovasculaires et la réduction de l'agrégation plaquettaire Download PDF

Info

Publication number
WO2007093020A1
WO2007093020A1 PCT/BR2006/000028 BR2006000028W WO2007093020A1 WO 2007093020 A1 WO2007093020 A1 WO 2007093020A1 BR 2006000028 W BR2006000028 W BR 2006000028W WO 2007093020 A1 WO2007093020 A1 WO 2007093020A1
Authority
WO
WIPO (PCT)
Prior art keywords
drug
treatment
platelet aggregation
hypertension
package
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/BR2006/000028
Other languages
English (en)
Inventor
Moreira De Almeida Igor
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Original Assignee
Bayer Healthcare AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Healthcare AG filed Critical Bayer Healthcare AG
Priority to PCT/BR2006/000028 priority Critical patent/WO2007093020A1/fr
Publication of WO2007093020A1 publication Critical patent/WO2007093020A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A61J1/03—Containers specially adapted for medical or pharmaceutical purposes for pills or tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J7/00—Devices for administering medicines orally, e.g. spoons; Pill counting devices; Arrangements for time indication or reminder for taking medicine
    • A61J7/04—Arrangements for time indication or reminder for taking medicine, e.g. programmed dispensers

Definitions

  • the present invention is presented under package or drug kit form or oral treatment presentation for treatment of hypertension, cardiovascular diseases and decrease platelet aggregation.
  • Blood pressure control is important to reduce risks and/or to prevent cardiovascular diseases, such as angina, myocardial infarction, among others.
  • Packaging system is just known.
  • Document US 2002/0045184 is related to a drug packaging system comprising packaging material comprising therein combined prescription drug therapy comprising one or more unit dosage forms of a first drug, wherein said first drug and second drug are independently selected from a group consisting of non-steroidal anti-inflammatory drugs, proton pump inhibitors, calcium channel blockers, angiotensin converting enzyme (ACE) inhibitors, anti-depressants, selective serotonin reuptake inhibitors, antihistamines, decongestants, biguanides, sulfonylureas, 3-hydroxy-3-methy!glutaryl coenzyme A (HMG CoA) reductase inhibitors, anti-epileptic, and anti diabetics.
  • ACE angiotensin converting enzyme
  • HMG CoA 3-hydroxy-3-methy!glutaryl coenzyme A
  • the invention comprises a nonsteroidal anti-inflammatory drug and said second drug comprises a proton pump inhibitor.
  • a proton pump inhibitor it is possible to select a drug from the group consisting of: omeprazole, lansoprazole, esomeprazole, pantoprazole, isomers, enantiomers or pharmaceutically acceptable salts thereof, preferably omeprazole.
  • non-steroidal anti-inflammatory drug it is possible to select a drug from the group consisting of: naproxen, diclofenac, sulindac, oxaprozin, diflunisal, aspirin, piroxicam, indomethacin, etodolac, ibuprofen, fenoprofen, ketoprofen, mefenamic acid, nabumetone, tolmetin, ketorolac, preferably diclofenac.
  • Document US 6273260 describes a packaging system for storing and dispering individual doses of medication on prescribed days wherein the individual dose of medication is an enteric fluoxetine pellet comprising: a) a core consisting of fluoxetine and one or more pharmaceutically acceptable excipients; b) an optional separating layer; c) an enteric layer comprising hydroxypropylmethylcellulose acetate succinate (HPMCAS) and one or more pharmaceutically acceptable excipients; d) an optional finishing layer.
  • HPMCAS hydroxypropylmethylcellulose acetate succinate
  • Document BR 9609559 describes a packaging system for storing pills that are administered in a gradually increasing dosage during the period of treatment.
  • Document BR MU8302502 deals about a packaging system or kit of medicaments for the treatment of arteriosclerotic disease, comprising one or more anti-thrombocyte agents, that may be: simvastatin, atorvastatin, pravastatin, lovastatin, fluvastatin and rosuvastatin, preferentially the simvastatin and one or more agents, capable to meliorate the lipid profile of blood, like the acetyl salicylic acid, or ticlopidine, preferentially the acetylsalicylic acid.
  • anti-thrombocyte agents that may be: simvastatin, atorvastatin, pravastatin, lovastatin, fluvastatin and rosuvastatin, preferentially the simvastatin and one or more agents, capable to meliorate the lipid profile of blood, like the acetyl salicylic acid, or ticlopidine, preferentially the acetylsal
  • Document BR MU8201733 deals about a packaging system or kit of medicaments, particularly for treating ulcerous gastro-intestinal problems, caused by the bacterium Helicobacter pylori, presenting one or more antibiotics like amoxicillin, erythromycin, metronidazole, tinidazole, preferentially amoxicillin and erythromycin and one or more inhibitors of the proton pump (IBP), like the lansoprazole, omeprazole, pantoprazole, rabeprazole, esomeprazole, preferentially the lansoprazole.
  • IBP proton pump
  • This invention is a matter of package, or drug kit, or drug smooth administering presentation for the treatment of hypertension, coronary disease chest pain and decrease platelet aggregation.
  • This invention describes a packaging system, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation, including in each outer carton, blister or similar one or more unit dosage forms of a platelet aggregation inhibitor agent and one or more unit dosage forms of a calcium antagonist agent, optionally associated with others synergic drugs wherein information are presented under clear orientation about active principles nature, dosage, day of week, period of the day when the drug must be taken, periodicity of the treatment and other technical information.
  • the mentioned invention provides easiness on the combination use of one antihypertensive drug and one platelet aggregation inhibitor drug, through its administration form that shows an additional benefit compared to the simple treatment.
  • the invention's objectives are: a) to emphasize the importance of the administration of both drugs together; b) to enhance treatment adhesion; c) to guarantee that both drugs are taken.
  • the outer carton, blister or similar brings written information that facilitates the patient's adhesion and the drug/product handle.
  • the outer carton, blister or similar contains two products: one anti-hypertensive of calcium antagonists, plain class and another one of platelet aggregation inhibitor class. First one is indicated for hypertension treatment, coronary disease and stable angina and the second to inhibit platelet aggregation in: instable angina, heart attack and others.
  • the presentation aims at the functionality relating to one already available in the market.
  • the mentioned drugs are already known in the market and are available in blisters, outer cartons or similar; however, they are commercialized on an independent way. It was developed a package or drug kit or drug smooth administration presentation of both drugs.
  • the product has didactic, safe and clear information that facilitates use and handling of the drugs.
  • Both of the drugs have, together, the whole of treating hypertension, cardiovascular diseases and decrease platelet aggregation.
  • the active principles that aim reducing or adjusting blood pressure comprising calcium antagonists, plain class may be selected from the group comprising: amlodipine, nifedipine, verapamil, felodipine, nitrendipine, isradipine, nisoldipine, diltiazem, mibefradil, manidipine, lacidipine and lercandipine, its mixtures, isomers, enantiomers or pharmaceutically acceptable salts thereof.
  • Unit dosage may vary from 10 mg to 1000 mg, optionally associated with others drugs, following medical orientation, preferably 20 mg, or 30 mg, or 60 mg per tablet unit.
  • the active principles that aim at inhibiting platelet aggregation in instable angina, heart attack and others may be selected from the group comprising: cilostazol, ticlopidine, acetylsalicylic acid, triflusal, dipyridamole, clopidrogel, abciximab, tirofiban, its mixtures, isomers, enantiomers or pharmaceutically acceptable salts thereof.
  • Unit dosages may vary from 10 mg until 1000 mg, optionally associated with others drugs, following medical orientation, preferably 100 mg, or 200 mg, or 300 mg per tablet unit.
  • the active principles can be presented under tablets, coated tablet, capsules, soft gel capsules, or any other pharmaceutically or galenic forms known by the man skilled in the art.
  • Said platelet aggregation inhibitor agent and / or calcium antagonist agent may be mixtures or associated with other synergic actives, like diuretics or others antihypertensives.
  • Package may comprise 28 or 14 or 7 tablets of a platelet aggregation inhibitor agents and 28 or 14 or 7 tablets of calcium antagonist agent, or any other amount suitable for the treatment period.
  • the invention is a packaging system, or a drug kit or a smooth administration presentation of both drugs in outer carton, blister or similar with one or more units of acetylsalicylic acid and one or more units of nifedipine, optionally associated with others drugs, with clear orientation about active principles nature, dosage, day of week, period of the day when the drug must be taken and periodicity of the treatment.
  • the invention is a package, or a drug kit or a smooth administration presentation with 28 or 14 or 7 tablets of each active principle, or others amounts suitable for the treatment, with unit dosages for 10 mg to 1000 mg of each tablet or each active, acetylsalicylic acid or nifedipine, or others synergic drugs. Dosages of each unit respects medical orientation and are supported by clinical trials which validate the concomitant use of these products following the mentioned dosages.
  • the suggested administration is one tablet of each active principle per day or under medical orientation, during the period established by the doctor or health professional.
  • the invention includes in each outer carton, blister or similar there are a dosage unit of nifedipine and a dosage unit acetylsalicylic acid, optionally associated with others drugs, presented under a clear and didactic way, which contains written technical and informative orientation about active principle, dosage, recommended dosage, day of week, period and periodicity. It may comprise 28 or 14 or 7 tablets of acetylsalicylic acid and 28 or 14 or 7 tablets of nifedipine for the treatment period, or any other amount suitable for the treatment.
  • Acetylsalicylic acid unit dosage is 100 mg, or 200 mg, or 300 mg and nifedipine unit dosage is 20 mg, or 30 mg, or 60 mg.
  • Package, or drug kit, or drug smooth administration presentation for the treatment of hypertension, cardiovascular diseases and decrease platelet aggregation is indicated for instable angina, heart attack and others kinds of diseases.
  • the following example aims at illustrating the invention or package, or drug kit or smooth administration presentation; however, it should not restrict the model draft.
  • FIGURE 1 attached, elucidates one of the outer carton of the package, according to the invention, as follow:
  • the figure represents the outer carton, containing units of medicines, according to the TABLE 1 , below:

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Medical Informatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

L'invention concerne un système de conditionnement, une trousse de médicaments ou une présentation d'administration médicamenteuse appropriée destinés au traitement de l'hypertension et de maladies cardiovasculaires et à la réduction de l'agrégation plaquettaire, et comprenant, dans chaque carton extérieur, plaquette alvéolaire ou analogue, une ou plusieurs formes posologiques unitaires d'un agent inhibiteur de l'agrégation plaquettaire et une ou plusieurs formes posologiques unitaires d'un agent antagoniste du calcium, éventuellement en association avec d'autres médicaments synergiques, les informations étant présentées avec clarté en ce qui concerne la nature des principes actifs, le dosage, le jour de la semaine, la période du jour à laquelle le médicament doit être pris, la périodicité du traitement et d'autres informations techniques, comme indiqué dans la figure 1. L'invention se rapporte à une présentation pour le traitement de l'hypertension et de maladies cardiovasculaires et la réduction de l'agrégation plaquettaire. La régulation de la pression artérielle est importante pour réduire les risques de maladies cardiovasculaires et/ou pour prévenir ces maladies, notamment l'angine de poitrine et l'infarctus du myocarde, entre autres.
PCT/BR2006/000028 2006-02-17 2006-02-17 Système de conditionnement, trousse de médicaments ou présentation d'administration médicamenteuse appropriée pour le traitement de l'hypertension et de maladies cardiovasculaires et la réduction de l'agrégation plaquettaire Ceased WO2007093020A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/BR2006/000028 WO2007093020A1 (fr) 2006-02-17 2006-02-17 Système de conditionnement, trousse de médicaments ou présentation d'administration médicamenteuse appropriée pour le traitement de l'hypertension et de maladies cardiovasculaires et la réduction de l'agrégation plaquettaire

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/BR2006/000028 WO2007093020A1 (fr) 2006-02-17 2006-02-17 Système de conditionnement, trousse de médicaments ou présentation d'administration médicamenteuse appropriée pour le traitement de l'hypertension et de maladies cardiovasculaires et la réduction de l'agrégation plaquettaire

Publications (1)

Publication Number Publication Date
WO2007093020A1 true WO2007093020A1 (fr) 2007-08-23

Family

ID=37001089

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/BR2006/000028 Ceased WO2007093020A1 (fr) 2006-02-17 2006-02-17 Système de conditionnement, trousse de médicaments ou présentation d'administration médicamenteuse appropriée pour le traitement de l'hypertension et de maladies cardiovasculaires et la réduction de l'agrégation plaquettaire

Country Status (1)

Country Link
WO (1) WO2007093020A1 (fr)

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010020147A1 (en) * 2000-02-28 2001-09-06 John Staniforth Delivery of oral drugs

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20010020147A1 (en) * 2000-02-28 2001-09-06 John Staniforth Delivery of oral drugs

Similar Documents

Publication Publication Date Title
US20020045184A1 (en) Packaging system
JP2004500967A (ja) 根絶治療のための医薬製品パッケージ
CN101969933B (zh) 通过包覆物结合的口服药物的组合
ES2307463T3 (es) Forma de dosificación de combinación que contiene un agente reductor del colesterol, un inhibidor de la renina-angiotensina, y aspirina.
US5830490A (en) Method and device for organizing and coordinating the combined use of topical aerosols and oral medications for the treatment of disorders
RU96112139A (ru) Фармацевтический препарат для перорального приема
JP2010532358A (ja) 咀嚼可能外層を有する配合剤
KR930009605A (ko) 소염 또는 진통제
US20050281868A1 (en) Transdermal delivery system for statin combination therapy
WO2001037831A1 (fr) Combinaison pharmaceutique comprenant des formes galeniques separees et placees dans un emballage souple, d'un inhibiteur de la hmg coa reductase et d'un derive de l'acide fibrique
WO2004004776A1 (fr) Combinaison pharmaceutique d'un antagoniste du recepteur de la thromboxane a2 et d'un inhibiteur du cox-2
RU2491070C2 (ru) Фармацевтическая композиция для профилактики и лечения сердечно-сосудистых заболеваний
US20060034913A1 (en) Multiplex drug delivery device
ES2611019T3 (es) Tratamiento de las quemaduras solares usando analgésicos y antihistamínicos
WO2007093020A1 (fr) Système de conditionnement, trousse de médicaments ou présentation d'administration médicamenteuse appropriée pour le traitement de l'hypertension et de maladies cardiovasculaires et la réduction de l'agrégation plaquettaire
EP1119501B1 (fr) Dispositif d'organisation de l'utilisation combinee d'aerosols topiques et de medicament oral
US20070003490A1 (en) Medicated gumstick for treatment in anti-inflammatory conditions and prophylaxis against NSAID gastropathy
WO2007093021A1 (fr) Conditionnement ou kit de médicaments ou présentation pour l'administration régulière de médicaments pour le traitement de l'hypertension, de l'angor et d'autres maladies cardiovasculaires.
AU2001273932B2 (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
RU2750934C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ, СОДЕРЖАЩАЯ ИНГИБИТОР ГМГ-КоА РЕДУКТАЗЫ И ИНГИБИТОР АПФ
US8865209B1 (en) Combined sublingual and gastro-intestinal delivery method of a liquid medication in a single volume limited dose
ES2811904T3 (es) Composición farmacéutica que comprende bisoprolol y perindopril
US20100035933A1 (en) Kits, Recloseable Containers, Blanks And Methods Of Treatment
AU2001273932A1 (en) Drug combination for the treatment of headache comprising mirtazapine and paracetamol or a non-steroidal anti-inflammatory drug
TH85149A (th) รูปแบบของการให้ยาทางปากซึ่งประกอบด้วย 5-[4-[2-(n-เมธิล-n-(2-ไพริดิล)อะมิโน)เอธอกซี]เบนซิล]ไธอะโซลิดีน-2,4-ไดโอน

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 06721588

Country of ref document: EP

Kind code of ref document: A1